Fry, J;
Honour, J;
(1998)
Understanding premenstrual syndrome.
The Lancet
, 351
(9114)
1511 - 1511.
10.1016/S0140-6736(05)78900-5.
![[thumbnail of Fry_%26 Honour 1998.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Fry_%26 Honour 1998.pdf Access restricted to UCL open access staff Download (46kB) |
Abstract
In her Feb 14 commentary, Sarah Berga rightly draws attention to the possible importance of progesterone and its neuroactive metabolites for our understanding of the premenstrual syndrome. She discusses the report of A J Rapkin and colleagues, who found serum concentrations of the progesterone metabolite allopreg-nanolone during the luteal phase to be lower in women with premenstrual syndrome than in symptom-free women. However, her explanation of the importance of this finding in terms of alternative pathways of progesterone metabolism to neuroactive compounds with different effects on the central nervous system (CNS) is incorrect and was never claimed by the original investigators.
Archive Staff Only
 |
View Item |
